HUE054898T2 - Kromán, izokromán és dihidroizobenzofurán származékok mint mGluR2-negatív allosztérikus modulátorok, kompozíciók és felhasználásuk - Google Patents

Kromán, izokromán és dihidroizobenzofurán származékok mint mGluR2-negatív allosztérikus modulátorok, kompozíciók és felhasználásuk

Info

Publication number
HUE054898T2
HUE054898T2 HUE17781253A HUE17781253A HUE054898T2 HU E054898 T2 HUE054898 T2 HU E054898T2 HU E17781253 A HUE17781253 A HU E17781253A HU E17781253 A HUE17781253 A HU E17781253A HU E054898 T2 HUE054898 T2 HU E054898T2
Authority
HU
Hungary
Prior art keywords
isochromane
mglur2
chromane
compositions
allosteric modulators
Prior art date
Application number
HUE17781253A
Other languages
English (en)
Inventor
Iyassu Sebhat
Ashok Arasappan
Scott Hoyt
Robert WILKENING
Duane Demong
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of HUE054898T2 publication Critical patent/HUE054898T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • A61K31/015Hydrocarbons carbocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/02Halogenated hydrocarbons
    • A61K31/025Halogenated hydrocarbons carbocyclic
    • A61K31/03Halogenated hydrocarbons carbocyclic aromatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22Bridged ring systems
    • C07D221/24Camphidines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HUE17781253A 2016-09-27 2017-09-25 Kromán, izokromán és dihidroizobenzofurán származékok mint mGluR2-negatív allosztérikus modulátorok, kompozíciók és felhasználásuk HUE054898T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662400150P 2016-09-27 2016-09-27

Publications (1)

Publication Number Publication Date
HUE054898T2 true HUE054898T2 (hu) 2021-10-28

Family

ID=60043302

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17781253A HUE054898T2 (hu) 2016-09-27 2017-09-25 Kromán, izokromán és dihidroizobenzofurán származékok mint mGluR2-negatív allosztérikus modulátorok, kompozíciók és felhasználásuk

Country Status (39)

Country Link
US (4) US10335399B2 (hu)
EP (1) EP3519416B1 (hu)
JP (3) JP6681517B2 (hu)
KR (1) KR102296043B1 (hu)
CN (1) CN109983022B (hu)
AR (1) AR109714A1 (hu)
AU (2) AU2017334870C1 (hu)
CA (1) CA3037537C (hu)
CL (1) CL2019000778A1 (hu)
CO (1) CO2019002673A2 (hu)
CR (1) CR20190147A (hu)
CY (1) CY1124346T1 (hu)
DK (1) DK3519416T3 (hu)
DO (1) DOP2019000076A (hu)
EA (1) EA038627B1 (hu)
EC (1) ECSP19020742A (hu)
ES (1) ES2868973T3 (hu)
GE (2) GEP20217266B (hu)
HR (1) HRP20210793T1 (hu)
HU (1) HUE054898T2 (hu)
IL (1) IL265366B (hu)
JO (1) JOP20190058B1 (hu)
LT (1) LT3519416T (hu)
MA (1) MA46342B1 (hu)
MD (1) MD3519416T2 (hu)
MX (1) MX2019003492A (hu)
MY (1) MY196807A (hu)
NI (1) NI201900025A (hu)
PE (1) PE20190609A1 (hu)
PH (1) PH12019500597A1 (hu)
PL (1) PL3519416T3 (hu)
PT (1) PT3519416T (hu)
RS (1) RS61890B1 (hu)
SI (1) SI3519416T1 (hu)
TN (2) TN2020000161A1 (hu)
TW (1) TWI764934B (hu)
UA (1) UA123687C2 (hu)
WO (1) WO2018063955A1 (hu)
ZA (1) ZA201901701B (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA46342B1 (fr) * 2016-09-27 2021-05-31 Merck Sharp & Dohme Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation
AU2019208331B2 (en) 2018-01-19 2024-05-02 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
BR112021017276A2 (pt) * 2019-03-01 2021-11-09 Kbp Biosciences Co Ltd Método para preparar composto tricíclico e intermediário do mesmo
BR112023017461A2 (pt) 2021-03-04 2023-09-26 Cytokinetics Inc Compostos, composição farmacêutica, métodos de tratamento de doença cardíaca, de uma doença ou afecção associada à cardiomiopatia hipertrófica, de uma doença ou afecção que está associada ao espessamento secundário da parede do ventrículo esquerdo, de uma doença ou afecção associada à pequena cavidade ventricular esquerda e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia miocárdica ou fibrose cardíaca, de uma doença ou afecção selecionada a partir de distrofias musculares e doenças de armazenamento de glicogênio, e, método de inibição do sarcômero cardíaco
WO2023278729A1 (en) * 2021-06-30 2023-01-05 The General Hospital Corporation Chromane imaging ligands

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552437A (en) 1994-10-27 1996-09-03 Merck Frosst Canada, Inc. Bisarylcarbinol derivatives as inhibitors of leukotriene biosynthesis
US5576338A (en) 1995-02-15 1996-11-19 Merck Frosst Canada, Inc. Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのhcvポリメラーゼ阻害剤としての利用
EP1934205A4 (en) 2005-10-05 2010-06-02 Merck Frosst Canada Ltd SUBSTITUTED QUINOLINES AS INHIBITORS OF LEUCOTRIENE BIOSYNTHESIS
AR065093A1 (es) 2007-02-05 2009-05-13 Merck Frosst Canada Ltd Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos
US20120040974A1 (en) 2008-08-18 2012-02-16 Yale University Mif modulators
MX2011011964A (es) * 2009-05-12 2012-02-23 Janssen Pharmaceuticals Inc Derivados de 1,2,3-triazolo[4,3-a]piridina y su uso para el tratamiento o prevencion de trastornos neurologicos y psiquiatricos.
US8772301B2 (en) 2009-12-18 2014-07-08 Sunovion Pharmaceuticals, Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
WO2013066736A1 (en) * 2011-11-03 2013-05-10 Merck Sharp & Dohme Corp. QUINOLINE CARBOXAMIDE AND QUINOLINE CARBONITRILE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
WO2016029454A1 (en) 2014-08-29 2016-03-03 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
US9382208B1 (en) 2015-01-26 2016-07-05 Vanderbilt University Negative allosteric modulators of metabotropic glutamate receptor 2
WO2016149324A1 (en) 2015-03-16 2016-09-22 Vanderbilt University Negative allosteric modulators of metabotropic glutamate receptor 2
JP6471614B2 (ja) 2015-05-29 2019-02-20 株式会社リコー 通信端末、通信システム、通信制御方法、及びプログラム
JP2018154554A (ja) 2015-07-29 2018-10-04 大日本住友製薬株式会社 新規リンカー部位を持つ縮合ピラゾール誘導体およびその医薬用途
MA46342B1 (fr) * 2016-09-27 2021-05-31 Merck Sharp & Dohme Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation

Also Published As

Publication number Publication date
CN109983022B (zh) 2022-06-07
JOP20190058B1 (ar) 2023-09-17
EP3519416A1 (en) 2019-08-07
KR20190056418A (ko) 2019-05-24
AU2017334870A1 (en) 2019-03-28
PL3519416T3 (pl) 2021-09-06
DK3519416T3 (da) 2021-05-25
GEP20217266B (en) 2021-06-25
TWI764934B (zh) 2022-05-21
IL265366B (en) 2021-12-01
JP6992109B2 (ja) 2022-02-15
LT3519416T (lt) 2021-06-10
MX2019003492A (es) 2019-09-19
CO2019002673A2 (es) 2019-03-29
US20190247374A1 (en) 2019-08-15
UA123687C2 (uk) 2021-05-12
IL265366A (en) 2019-05-30
SI3519416T1 (sl) 2021-08-31
HRP20210793T1 (hr) 2021-09-03
TN2020000161A1 (en) 2022-04-04
US10335399B2 (en) 2019-07-02
BR112019005869A8 (pt) 2023-05-02
ECSP19020742A (es) 2019-04-30
PE20190609A1 (es) 2019-04-23
JP6681517B2 (ja) 2020-04-15
US20210015800A1 (en) 2021-01-21
ES2868973T3 (es) 2021-10-22
MD3519416T2 (ro) 2021-09-30
JOP20190058A1 (ar) 2019-03-24
NI201900025A (es) 2019-05-27
JP6945605B2 (ja) 2021-10-06
AR109714A1 (es) 2019-01-16
PT3519416T (pt) 2021-05-13
US20220218676A1 (en) 2022-07-14
US20180085358A1 (en) 2018-03-29
CR20190147A (es) 2019-05-17
ZA201901701B (en) 2023-03-29
MA46342A (fr) 2019-08-07
TW201815794A (zh) 2018-05-01
JP2020011989A (ja) 2020-01-23
US10806724B2 (en) 2020-10-20
AU2020270468B2 (en) 2022-02-17
CN109983022A (zh) 2019-07-05
TN2020000160A1 (en) 2022-04-04
CA3037537A1 (en) 2018-04-05
WO2018063955A1 (en) 2018-04-05
CL2019000778A1 (es) 2019-05-31
AU2017334870C1 (en) 2020-12-17
AU2020270468A1 (en) 2020-12-10
PH12019500597A1 (en) 2019-07-24
BR112019005869A2 (pt) 2019-06-11
CA3037537C (en) 2021-06-15
KR102296043B1 (ko) 2021-08-30
EA038627B1 (ru) 2021-09-24
JP2019529468A (ja) 2019-10-17
MY196807A (en) 2023-05-03
RS61890B1 (sr) 2021-06-30
JP2020111596A (ja) 2020-07-27
MA46342B1 (fr) 2021-05-31
DOP2019000076A (es) 2019-07-15
AU2017334870B2 (en) 2020-08-20
CY1124346T1 (el) 2022-07-22
EP3519416B1 (en) 2021-03-31
GEP20217279B (en) 2021-08-10
EA201990818A1 (ru) 2019-08-30

Similar Documents

Publication Publication Date Title
HK1256608A1 (zh) 類黃酮組合物及其使用方法
ZA201901701B (en) Chromane, isochromane and dihydroisobenzofuran derivatives as mglur2-negative allosteric modulators, compositions, and their use
EP3383447A4 (en) PHOTOACTIVATED PREPARATION OF HYDROGELS
EP3380096A4 (en) CANNABIS OIL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
EP3139920A4 (en) Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
EP3201187A4 (en) Compositions and methods for inhibiting bmp
EP3288553A4 (en) Combinations of cannabinoids and n-acylethanolamines
IL252311A0 (en) 4-oxo-4,3-dihydro-3,2,1-benzotriazines as G protein-coupled receptor modulators 139
EP3535252A4 (en) COMPOSITION COMPRISING A COMBINATION OF EPICATECHIN AND ANTI-CANCER COMPOUND
EP3122355A4 (en) Compositions and methods for inhibiting bmp
EP3472176A4 (en) THE USEFULNESS OF (+) EPICATECHIN AND THEIR ANALOGS
EP3185865A4 (en) TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
EP3355881A4 (en) ORAL TAXANE COMPOSITIONS AND RELATED METHODS
ZA201508973B (en) Chromane and chromene derivatives and their use as crac modulators
EP3111939A4 (en) Vitamin d and antibacterial uses of composition thereof
PL3468964T3 (pl) Modulatory soce, ich kompozycje i zastosowania
EP3512834A4 (en) INHIBIT OF BMP SIGNALING, CONNECTIONS, COMPOSITIONS AND USES THEREOF
EP3109242B8 (en) Water-soluble taxane derivatives and uses thereof
EP3277274A4 (en) Anti-methanogenic lovastatin analogs or derivatives and uses thereof
HK1257091A1 (zh) 茚烷衍生物作為mglur7調節劑
EP3201204A4 (en) C5-c6-fused tricyclic iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP3397627A4 (en) INDOLIZIN DERIVATIVES, COMPOSITION AND METHODS OF USE
EP3371192A4 (en) PODOPHYL LOTOXIN DERIVATIVES AND THEIR USE
IL259900A (en) Aminoazole derivatives, compositions containing same and uses thereof
AU2016902397A0 (en) Composition containing Proanthocyanidins